Outcomes of transferring embryos identified as abnormal
Transfer of Aneuploid or Mosaic Embryos Following Preimplantation Genetic Testing
NA · Stanford University · NCT04109846
This study is testing whether transferring embryos that are found to have genetic abnormalities can lead to successful pregnancies and healthy children for patients who have no other viable embryo options.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | Female |
| Sponsor | Stanford University (other) |
| Locations | 1 site (Sunnyvale, California) |
| Trial ID | NCT04109846 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the outcomes of pregnancies resulting from the transfer of embryos that have been identified as aneuploid or mosaic through preimplantation genetic testing. It will evaluate the frequency of live births from these embryos and investigate any associated risks for complications during pregnancy and potential health or developmental issues in the children during their first five years. Participants will provide medical records and pediatric data, and the study will meticulously document genetic testing results and pregnancy outcomes. The research is conducted at Stanford University, focusing on patients with no other viable embryo options.
Who should consider this trial
Good fit: Ideal candidates are individuals with available aneuploid or mosaic embryos and no other acceptable embryos, who are willing to travel to Stanford for treatment.
Not a fit: Patients using international donor eggs or sperm not tested according to FDA guidelines, or those living outside the United States, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights into the safety and viability of transferring embryos deemed abnormal, potentially improving reproductive outcomes for patients.
How similar studies have performed: While there have been studies on embryo transfer outcomes, this specific focus on aneuploid and mosaic embryos is relatively novel and not extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Available aneuploid or mosaic embryos * No other acceptable embryos available * Willing to travel to Stanford for treatment * English language fluency Exclusion Criteria: * Use of international donor eggs or sperm not tested according to FDA guidelines. * Living outside the United States * Embryos with Triploidy are not eligible for transfer in this protocol
Where this trial is running
Sunnyvale, California
- Stanford Fertility and Reproductive Medicine Center — Sunnyvale, California, United States (RECRUITING)
Study contacts
- Principal investigator: Ruth Lathi, MD — Stanford University
- Study coordinator: Ronit Mazzoni, MS
- Email: rmazzoni@stanford.edu
- Phone: 408-688-9892
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Aneuploidy, Mosaicism, Pregnancy Outcome, Preimplantation Genetic Testing for Aneuploidy, Preimplantation Genetic Screening, embryo transfer, mosaic, aneuploid